2026. Therapeutic Antibody Half-Life Extension: Engineering Choices and Their Clinical Consequences. Translational Medicine & Therapeutics Journal. 5, 1 (Jul. 2026), 74–82. DOI:https://doi.org/10.5281/zenodo.22649501.